Willis Johnson & Associates’s Verona Pharma VRNA Stock Holding History

Willis Johnson & Associates’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,285	Closed	-$244K	–	201
2025 Q3	$244K	Hold	2,285	–	–	0.02%	161
2025 Q2	$216K	Buy	+2,285	New	+$169K	0.01%	155

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Willis Johnson & Associates's VRNA Position: Q4 2025 in Review

Willis Johnson & Associates sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 2,285 shares — an estimated $244K sold.

Willis Johnson & Associates first reported a position in VRNA in Q2 2025 and held it in 2 quarters. The position peaked at $244K in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Willis Johnson & Associates reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Willis Johnson & Associates sold 2,285 Verona Pharma shares in Q4 2025, an estimated $244K.
Willis Johnson & Associates first reported a position in Verona Pharma in Q2 2025 and held it in 2 quarters.
Willis Johnson & Associates's Verona Pharma position peaked at $244K in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Willis Johnson & Associates's 13F filing for Q4 2025, filed 22 Jan 2026.